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Abstract
Based on models with calibrated parameters for infection, case fatality rates, and vaccine efficacy, basic
childhood vaccinations have been estimated to be highly cost effective. In this paper, we estimate the as-
sociation of vaccination with mortality directly from survey data. Using 149 cross-sectional Demographic
and Health Surveys, we determine the relationship between vaccination coverage and under five mortality
at the survey cluster level. Our data include approximately one million children in 68,490 clusters in
62 countries. We consider the childhood measles, Bacille Calmette-Gue´rin (BCG), Diphtheria-Pertussis-
Tetanus (DPT), Polio, and maternal tetanus vaccinations. Using modified Poisson regression to estimate
the relative risk of child mortality in each cluster, we also adjust for selection bias caused by the vac-
cination status of dead children not being reported. Childhood vaccination, and in particular measles
and tetanus vaccination, is associated with substantial reductions in childhood mortality. We estimate
that children in clusters with complete vaccination coverage have relative risk of mortality 0.73 (95%
Confidence Interval: 0.68, 0.77) that of children in a cluster with no vaccination. While widely used,
basic vaccines still have coverage rates well below 100% in many countries, and our results emphasize
the effectiveness of increasing their coverage rates in order to reduce child mortality.
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1 Introduction
There is evidence that vaccines are effective in children against specific diseases such as tuberculosis (Colditz
et al., 1994), measles (Goldhaber-Fiebert et al., 2010), and tetanus (Koenig et al., 1998; Van Den Ent et al.,
2011), and increases in vaccine coverage have therefore been seen as an important strategy for reducing infant
and child mortality (Feikin et al., 2015). There have been a series of coordinated global efforts to increase
immunization rates in developing countries as a means of achieving improvements in child health, including
the Expanded Program on Immunization (EPI), initiated in 1974, and the Global Alliance for Vaccines and
Immunization (GAVI), initiated in 2000 (Brenzel et al., 2006). The period from 2010-2019 has been termed
the “Decade of Vaccines” (Stack et al., 2011). Largely due to donor funds, the coverage of vaccination
(as measured by the proportion of children receiving three doses of the diphtheria-tetanus-pertussis vaccine
by 12 months of age - DPT3) increased substantially, from 5% or less in 1974, to 75% in 1990, to 84%
in 2013, albeit with important regional, national, and sub-national variation in achieved coverage (Burton
et al., 2009; Harris et al., 2014). Increases in coverage in Africa were achieved with a series of supplementary
immunization activities (SIA) in the late 1990s, which were successful in reaching 24 million children between
1996 and 2000 (Biellik et al., 2002).
Almost 20 million children failed to receive DPT3 in 2010, a third of whom were in Africa, and mainly
concentrated in 10 countries (Bosch-Capblanch et al., 2012). In addition, other vaccines have lower levels
of coverage, with much lower rates for measles than for DPT3. While the numbers of vaccine-preventable
deaths are large, the proportion of deaths caused by vaccine-preventable diseases appears to be relatively
small, for example, measles accounted for 4% of all childhood deaths under the age of five in the period
2000-2003, while tetanus accounted for a further 7%, with much smaller impacts from the other diseases
(Bryce et al., 2005). These figures had reduced even further by 2008 (Black et al., 2010). Nevertheless,
studies of the cost effectiveness of vaccination using only the effect on disease specific mortality find it highly
cost effective (Bishai et al., 2011).
However, there is potential for routine vaccines to have an impact above and beyond the expected as-
sociation with the specific disease. For example, the introduction of the measles vaccine in some African
communities in the 1980s led to a far greater reduction in overall child mortality than would be expected
from reductions in measles mortality alone (Aaby et al., 1984). Similar large effects of all-cause mortality
were found after the introduction of measles vaccination in Matlab, Bangladesh (Aaby et al., 2003; Clemens
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et al., 1988; Koenig et al., 1998). These findings have been replicated in other settings, including in Ran-
domized Control Trials (RCTs) (Aaby et al., 2010, 1995; Holt et al., 1990). There is also some evidence that
the Bacillus Calmette-Gurin (BCG) is protective against neonatal morality, and some suggestion that DPT
vaccination may increase mortality in some settings (Aaby et al., 2012, 2004a). The hypothesis that vaccines
have non-specific effects on mortality has received validation in animal studies demonstrating a plausible
mechanism for these effects. Administration of BCG vaccine in mice led to trained immunity via epigenetic
reprogramming (Kleinnijenhuis et al., 2012).
Despite recent progress in reducing under five mortality (Liu et al., 2012), there has been a renewed focus
on implementing interventions to allow countries to reach the target of a reduction in child mortality of two
thirds from its 1990 level as set by the fourth Millennium and Development Goal (MDG). Immunization may
provide a highly cost effective mechanism for further reducing child mortality. However, many studies on
vaccine cost effectiveness rely on calibration studies and simulation exercises, with measures of the association
between vaccination status and mortality often taken from specific cohorts in localized areas (Bishai et al.,
2011; Verguet et al., 2013). There are likely to be important differences both across and within countries in
terms of the effectiveness of vaccination. One issue is how vaccines are administered, a factor which could
potentially affect vaccine efficacy. For example, there is substantial variation in the timing of vaccination
in low and middle income countries (Clark and Sanderson, 2009). A second issue is that actual vaccine
effectiveness may be lower in practice in large scale implementation than in small scale studies (Uzicanin
and Zimmerman, 2011), due to failures of the cold chain, storage, and handling. A third issue is that the
effectiveness of vaccination in reducing child mortality may depend on other factors, for example their family’s
socio-economic status and the child’s nutrition (Koenig et al., 2001), making the average effectiveness in a
population differ from that found in small studies.
From a policy perspective, it is important to understand whether previous findings from RCTs and obser-
vational studies based on specific cohorts can be generalized to diverse populations who experience different
levels of economic development, disease environment, and health care systems (Sachdev, 2014). With some
exceptions (Aaby et al., 1995), relatively few previous studies have examined the relationship between basic
childhood vaccines and all-cause mortality with population-based data in more than a limited number of
countries; most past studies have relied on data from a single location. The advantage of our approach is
that we use nationally representative data from multiple countries that reflect a wide variety of populations
and are likely to have good external validity (Fink et al., 2011). Our data have information on all basic
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vaccines, and mortality data up to five years of age. Our methodological contribution is that we introduce
a correction for potential selection bias induced by missing data on children who have died.
This paper uses information from a large number of developing countries using Demographic and Health
Surveys (DHS) to examine the relationship between cluster level vaccination coverage and cluster level
under five mortality. We focus on the association between all-cause mortality and the measles, Bacille
Calmette-Gue´rin (BCG), DPT, Polio and maternal tetanus vaccinations, while controlling for the cluster’s
socio-economic and demographic characteristics. The goal of this paper is to establish the relationship
between mortality and immunization in population based data. Given recent findings in the literature, we
hypothesize larger impacts of the basic childhood vaccines than would be expected from their association
with cause specific mortality alone.
2 Methods
2.1 Data
We combined all publicly available datasets from the DHS for which we were able to measure child mortality,
the vaccination status of living children for all five basic vaccines, and household wealth (which is based on
an asset index). The DHS are nationally representative samples, typically of those aged 15-49, in developing
countries which have been conducted since 1980 (Corsi et al., 2012; Fabic et al., 2012; Hancioglu and Arnold,
2013). Detailed birth histories are collected from women documenting all children born in the previous five
years, together with the current status of these children (Fink et al., 2011). Our sample includes around
1 million births in 62 countries and 149 surveys, born between 1985 and 2011. Most DHS surveys include
vaccination status for one dose of BCG, DPT 1-3, Polio 1-3, one dose of measles, and maternal tetanus.
We excluded surveys from DHS round 1 as in the first wave vaccination status was typically recorded from
vaccination cards alone, resulting in a high proportion of missing values, whereas later surveys include the
mother’s report of their children’s vaccination status. Overall, 13% of children in the sample are reported as
not having a card, while a further 30% do not have their card presented to the interviewer. If the vaccination
card is not available, mothers are asked to report vaccination status. We define vaccination status according
to either the vaccination card, or when unavailable, as reported by the mother. Langsten and Hill show
that maternal reporting of BCG status in Egypt is 98% accurate, compared to 83% for DPT3 (Langsten
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and Hill, 1998). More recently, Murray and colleagues do not find any evidence that maternal recall bias
affects coverage estimates in the DHS (Murray et al., 2003). However, the mother-reported information is
an important limitation to the data (Cutts et al., 2013).
World Health Organization (WHO) recommendations for vaccination have changed over time, in part
reflecting updated evidence on the effectiveness of vaccines, and changing priorities from variation in coverage
rates. For example, initially the EPI recommended one dose of measles containing vaccine (MCV1), however
two doses are now standard in many countries as vaccination failure typically occurs in 10-15% of infants
receiving the first dose at 9 months (World Health Organization, 2009). Failure rates are likely to be
even higher if immunization occurs before 9 months due to immaturity of the immune system. The WHO
recommends prioritizing the first measles dose until 80% coverage of MCV1 for three consecutive years
has been achieved (World Health Organization, 2009). Regarding Polio, in high risk countries an Oral
Polio Vaccine (OPV) birth dose (Polio 0) followed by a primary series of three OPV doses and at least
one Inactivated Poliovirus Vaccine (IPV) dose is now recommended (World Health Organization, 2010).
As relatively few DHS surveys include information on Polio 0 or a second measles containing vaccination
(MCV2), we are restricted to the five types (BCG, DPT 1-3, Polio 1-3, MCV1, and maternal tetanus) if we
wish to use all available datasets. Our data does not distinguish between a monovalent measles vaccine and
the combined measles, mumps, and rubella (MMR) vaccine, or between IPV and OPV. A summary schedule
for the relevant vaccines is presented in table 1.
Table 1: World Health Organization Vaccination Schedule
Vaccine Typical 1st Dose Recommended Doses Usual Interval Between Doses
BCG At Birth 1
DPT 6 Weeks 3 4 Weeks
Polio Birth/6 weeks 4/3 4 Weeks
Measles 9/12 Months 1/2 4 Weeks
Maternal Tetanus Pregnancy Depends on Vaccination History
Note: A more comprehensive account of when vaccines are to be administered is available from
the WHO. See www.who.int/immunization/policy/Immunization routine table2.pdf for infants, and
www.who.int/reproductivehealth/publications/maternal perinatal health/immunization tetanus.pdf for maternal tetanus.
See www.who.int/immunization/monitoring surveillance/routine/coverage/en/ for WHO coverage estimates, and
www.unicef.org/supply/files/MMR.pdf and http://www.unicef.org/supply/files/TT.pdf for cost estimates.
As DPT and Polio vaccinations are typically administered at the same time, we found it is not possible
to separately identify the impact of each type, since children tend to have both or neither, making them
collinear. We combine DPT and Polio into a single variable where each dose counts for 1/6. Therefore,
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receiving a full schedule of DPT and Polio results in a score of 1. For the other child vaccinations (BCG
and measles), we construct a binary variable for each child indicating whether they received the relevant
vaccine dose. In addition, women report the number of tetanus toxoid injections received during their last
pregnancy, and we use this as a child health intervention since immunity to tetanus is transferred to the child
in utero (Demicheli et al., 2013). As the recommended dose varies depending on the woman’s vaccination
history, we construct an indicator for whether any tetanus vaccinations were received during pregnancy. We
did not find any association with a second tetanus vaccination. We have data on maternal tetanus injections
only for the pregnancies in the last five years, which does not give information about injections during prior
pregnancies. Even if the mother is not injected during the most recent pregnancy, she may have continuing
immunity from the prior vaccinations which we will not be able to measure in our data.
A complication is that childhood vaccination information in the DHS is typically only collected for children
who are alive, a common limitation of survey data, and so we cannot match child mortality to childhood
vaccinations at the individual level (except for maternal tetanus vaccination, which is recorded for all women
in our sample). To avoid this problem, we aggregate the data on mortality and vaccination coverage to
the level of the DHS primary sampling unit (PSU) cluster. The Demographic and Health Survey in each
country adopts a multistage sampling approach which involves first stratification by region, and then by
urban and urban rural residence within each region (Corsi et al., 2012). Potential sampling units are defined
by geographic localities, usually enumeration areas from the most recent national census. Primary sampling
units, our clusters, are randomly selected from these enumeration areas within each strata. Once these
primary sampling units are chosen, interviewers visit the area and sample a subset of the households in that
location to identify and interview eligible respondents. When we aggregate our data to the cluster level, we
are therefore calculating sample averages for localized geographic areas based on households which are in
close proximity.
As we expect an association between vaccination status and mortality, the vaccination rate among the
children who have died may differ from the vaccination rate among the children who survive, and ignoring
the missing data could induce selection bias in our estimates of cluster vaccination rates, as well as in our
estimates of the association between vaccination status and mortality (Jensen et al., 2007). Therefore, we
implement a correction for this problem based on Bayes’ rule (Reniers and Eaton, 2009), and an initial
estimate of the relative risk of mortality for each vaccination type which we obtain from the data.
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2.2 Correcting Estimates of the Impact of Vaccination Coverage for Missing
Data
The proportion of children vaccinated in a particular cluster (p(vacc)) is given by vaccination rate among
children who have died (p(vacc|dead)), weighted by the proportion of children in that cluster who have
died (Dead), plus the vaccination rate among the children who are alive (p(vacc|alive)), weighted by the
proportion of children in that cluster who are alive (Alive).
p(vacc) = p(vacc|dead).Dead+ p(vacc|alive).Alive
p(vacc|dead) is unobserved, however by Bayes’ Rule we can write this expression as a function of the
relative risk of mortality for vaccination status.
p(vacc|dead) = p(dead|vacc).p(vacc)
p(dead|vacc).p(vacc) + p(dead|not vacc).(1− p(vacc))
Dividing above and below by p(dead|vacc), this equates to:
p(vacc)
p(vacc) + (1− p(vacc)).RR(dead|not vacc)
Where RR(dead|not vacc) is the relative risk of mortality for those who were not vaccinated, given by
p(dead|not vacc)
p(dead|vacc) . It follows that we can derive a correction to the observed vaccination rate using this relative
risk to calculate the true vaccination rate in the cluster based on the solution to the following equation:
p(vacc) =
p(vacc)
p(vacc) + (1− p(vacc)).RR(died|not vacc) .Dead+ p(vacc|alive).Alive
Assuming the proportion of dead and living children, as well as the relative risk, is known, we then have a
single equation with one unknown (p(vacc)). The proportion of surviving children (Alive) and the proportion
of children who have died (Dead) in each cluster can be obtained from the data, however using the observed
values in calculating the corrected vaccination rates is problematic. The proportion of children who have
died, Dead = (1 − Alive), is essentially the dependent variable in our regression analysis, which is what
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we are trying to explain. Using the outcome directly as a component of our explanatory variable clearly
opens the argument that the explanation is vacuous. More formally, the error term in our regression analysis
clearly contributes to the outcome (Dead), and hence any explanatory variable that included the actual value
of Dead as a component is going to be correlated with the error term, violating the assumptions required
for estimation. Therefore, we replace these terms with the expected cluster mortality and survival rates
(E(Alive) and E(Dead)), which we estimate from the Poisson model described below. These terms are
functions of the existing explanatory variables alone, and correct, in expectation, the bias induced by only
measuring the vaccination status of living children. Then, solving for p(vacc) using the standard quadratic
formula, we obtain:
p(vacc) =
(−E(Dead)− p(vacc|alive).E(Alive) +RR(died|not vacc) + p(vacc|alive).E(Alive).RR(died|not vacc))
2(RR(died|not vacc)− 1)
±(√
(− 4.p(vacc|alive).Alive.(RR(died|not vacc)− 1).RR(died|not vacc) + (E(Dead) + p(vacc|alive)




This equation will have one root in the interval 0-1 (Reniers and Eaton, 2009). We can estimate each of
the quantities on the right hand side from the data, and use this formula to obtain corrected estimates of
vaccination coverage for DPT/Polio, BCG, measles, and the mean vaccination rate (BCG0, DPT/Polio0,
Measles0,V accination Mean0) for each cluster using the following procedure. We firstly estimate the
relative risk of mortality (calculated as the ratio of predicted mortality for 0% coverage relative to 100%
coverage), RR(died|not vacc)0, separately for each vaccination type using a Poisson regression model, ad-
justing for covariates, and the observed vaccination rates in each cluster. Then, we obtain the predicted
mortality and survival rates in each cluster from this model (E(Alive) and E(Dead)), as well as the first
iteration of the corrected estimate of vaccination coverage for each vaccination type (BCG1, DPT/Polio1,
Measles1, V accination Mean1) in each cluster using this estimate of relative risk and the formula above.
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The relative risk for vaccination type is then re-calculated using the corrected coverage rates to obtain
RR(died|not vacc)1. We iterate over this procedure 10 times to obtain a final estimate of corrected cov-
erage (BCG10, DPT/Polio10, Measles10, V accination Mean10) and a final estimate of the relative risk
(RR(died|not vacc)10). Overall, the coverage rates are not much affected by the omission of data on children
who have died, and in particular, the estimated coverage rates barely change after the first iteration, as shown
in Table A3 in the appendix. In general, this will be the case unless both mortality and the relative risk of
mortality from not being vaccinated is very high. We use these corrected coverage rates as our independent
variables in the model presented in table 2.
2.3 Poisson Regression Model
This approach, where we aggregate at the cluster level, gives us 68,490 observations. We excluded an
additional 79 clusters where the predicted mortality was 100%, as this would have result in a corrected
vaccination rate of 0% for these clusters. However, we have verified that our results are not sensitive to their
inclusion. Following the previous literature (Murray et al., 2003), we define the four vaccination rates in a
cluster as the proportion of children surviving to 12 months who had received the relevant doses (a single
dose for BCG and measles, the combined 6 doses of DPT and Polio, and whether the mother had received a
tetanus shot during pregnancy), therefore clusters without any surviving children aged 12 months or greater
are excluded from the analysis. We additionally estimate the average vaccination rate in a cluster as the
mean of these four indicators. Figure A1 in the appendix is a histogram showing the distribution of average
vaccination coverage across clusters.
We use modified Poisson regression to estimate the relative risk for the average vaccination rate using the
following model (Frome and Checkoway, 1985):
λc = exp(α+ β Vaccination Ratec +X
′
cγ + µc)
Where λc is the number of children in the cluster who have died, α is a constant, V accinationRatec is the
average vaccination rate in the cluster, β is the associated parameter measuring relative risk of vaccination
coverage, Xc are the independent variables measured at the cluster level, γ is the parameter vector associated
with these control variables, and µc is an error term. Xc includes the number of births in the cluster with
the coefficient offset to 1, so the number of child deaths is proportional to the number of births, and the
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other explanatory variables affect the mortality rate. We included deaths of children under the age of one in
our analysis (even though they may have been too young to have received all basic vaccinations) to capture
potential spillover effects, however when we excluded this age group we found very similar results. The
advantage of the Poisson model is that is allows us to estimate the relative risk directly. The expected
mortality rates for use in our correction for missing data can then be obtained from:
̂E(Dead)c = exp(αˆ+ βˆ Vaccination Ratec +X ′cγˆ)Number of Birthsc
Using the estimated regression parameters (αˆ, βˆ, γˆ) from our Poisson model. We also estimate the relative
risk for each of the 4 vaccination types (BCG, DPT/Polio, measles, and maternal tetanus) using a model
where we control for all four vaccination types simultaneously.
A potential concern with our model is that the vaccination rate is correlated with some other feature of
the cluster which we do not adequately measure, such as underlying disease environment (Fine et al., 2009).
If this omitted variable is correlated with vaccination coverage, our estimates of the effects of vaccination
coverage could be biased. We control for this to the extent possible using measured covariates in the clusters.
Table A2 in the appendix gives the full results showing these covariates.
All of our other independent variables are also aggregated to the cluster level; they include year of birth,
number of siblings, gender, place of birth, birth interval, mother’s age, type of place of residence (urban or
rural), mother’s education, flush toilet access, piped water access, mother’s partner’s education, mother’s
marital status, mother’s religion, household wealth index, and whether the mother had antenatal visits for
that pregnancy. We also control for months between the interview and birth as a measure of exposure risk,
country-specific fixed effects and time trends.
3 Results
Table 2 presents results for vaccination coverage using the Poisson regression model described above, with
cluster child mortality as the dependent variable and adjusting for other cluster characteristics. Columns
2 and 4 present results using coverage rates which are adjusted for missing data on children who have
died. Using the raw coverage rate, in Column 1 of Table 2, an increase in the mean vaccination coverage
is associated with a relative risk of 0.76, that is to say moving from 0% coverage to 100% coverage on all
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vaccination types (BCG, DPT/Polio, measles, and maternal tetanus) is associated with a decrease in cluster
level mortality of 24%. Column 2, which corrects for the selection effect of not measuring vaccination status
of the dead children, implies a slightly lower relative risk of mortality of 0.73.
We also implement a model where we test whether the mix of vaccines affects mortality. This is reported in
Columns 3 and 4 of Table 2. The mix of vaccination in a cluster is likely to depend on the available supply,
and factors such as donor funds or campaigns initiated as part of supplementary immunization activities
(SIA) (Biellik et al., 2002; Otten et al., 2005). Column 3 disaggregates the vaccination types, and column 4
does the same using the vaccination data that has been corrected for mortality selection. The results indicate
that measles is associated with a relative risk of 0.83, while maternal tetanus is associated with a relative
risk of 0.92. Thus, most of our estimated effect of overall vaccination on cluster mortality comes from these
two vaccines, the effects of BCG, DPT and Polio vaccination appear to be very small.
Table 2: Results for Poisson Model of Cluster Vaccination Coverage and Cluster Mortality
Relative Risk Relative Risk Relative Risk Relative Risk
Cluster Level Cluster Level Cluster Level Cluster Level
Under 5 Mortality Under 5 Mortality Under 5 Mortality Under 5 Mortality
Variables (95% CI) (95% CI) (95% CI) (95% CI)
Cluster Vaccination Average Coverage 0.76 (0.71, 0.81) 0.73 (0.68, 0.77)
Cluster BCG Coverage 1.04 (0.96, 1.12) 1.03 (0.96, 1.11)
Cluster DPT Polio Coverage 0.97 (0.89, 1.06) 0.97 (0.89, 1.06)
Cluster Measles Coverage 0.83 (0.77, 0.89) 0.83 (0.78, 0.89)
Cluster Maternal Tetanus Coverage 0.92 (0.86, 0.97) 0.92 (0.86, 0.97)
Corrected for Missing Data on Children who Died No Yes No Yes
Country Fixed Effects and Country Time Trends Yes Yes Yes Yes
Full Set of Control Variables Yes Yes Yes Yes
Number of Clusters 68,490 68,490 68,490 68,490
Note: Demographic and Health Survey data are available from www.dhsprogram.com. All variables are averages at the level of
the DHS primary sampling unit cluster, based on 149 surveys in 62 countries, and 960,271 children born between 1985 and 2011.
Coefficients illustrate the relative risk of moving from 0% vaccination coverage to 100% coverage (on the mortality of children
born in the 5 years prior to interview). Columns 1 and 3 are based on the raw vaccination coverage in a cluster (defined as the
proportion of children one year or older who have received the relevant doses), while columns 2 and 4 adjust the vaccination
data for the selection effect due to non-reporting of vaccination status of children who have died. In addition to country fixed
effects, country time trends, the control variables (all cluster level averages) include year of birth, gender, place of birth, birth
interval, mother’s age, type of place of residence, mother’s education, flush toilet access, piped water access, mother’s partner’s
education, mother’s marital status, mother’s religion, household wealth index, number of siblings, and whether the mother had
antenatal visits for that pregnancy. We also control for months between the interview and birth as a measure of exposure risk.
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4 Discussion
Our results imply that vaccination coverage has a substantial impact on under five mortality at the cluster
level, particularly for measles and maternal tetanus vaccination. These results are consistent with recent
evidence on the non-specific effects of vaccines from previous observational studies, animal studies and
randomized control trials (Shann, 2010). On the basis of these findings, there are therefore likely to be
substantial reductions in child mortality associated with further increases in vaccination coverage, particu-
larly additional immunization associated with measles and maternal tetanus in sub-Saharan Africa, where
vaccination rates lag behind other regions (Bosch-Capblanch et al., 2012).
Our population-level estimates provide new evidence on the association between all-cause mortality and
coverage of basic childhood vaccinations using nationally representative samples in diverse settings across 62
countries. Generally, it is not possible to estimate the association between vaccination status and mortality
at the individual level in household survey data, such as the DHS, because the vaccination status of children
who have died is not usually reported (Cutts et al., 2013). Our approach of aggregating the data and
correcting for this potential selection bias allows us to estimate this relationship at the cluster level. An
additional advantage of this aggregate analysis is that it allows us to capture potential herd immunity
effects (John and Samuel, 2000; VanderWeele and Tchetgen, 2011; VanderWeele et al., 2012), which would
not typically be observed in an individual-level analysis. Moreover, our focus on all-cause mortality avoids
the issue of misreporting of cause of death in studies that use cause-specific mortality (Dabbagh et al.,
2009), and allows for the possibility of non-specific effects of vaccination. There is typically substantial
variation in vaccination coverage within countries and even within regions (Bosch-Capblanch et al., 2012),
and conducting the analysis at these higher levels of aggregation will mask this heterogeneity and potentially
attenuate estimates of the effects of interest. DHS clusters are small geographic areas, and therefore the
households in each cluster are in close proximity, making this the ideal unit of analysis to investigate the full
impact of vaccine coverage. Demonstrating that similar estimates are obtained from a variety of different
estimation strategies in a variety of different populations strengthens the case for increasing vaccination
coverage as an effective intervention to improve child health in low and middle income countries (Concato
et al., 2000).
There were 7.6 million child deaths in 2010, down from 9.6 million in 2000, a reduction in the under five
mortality rate from 73 to 57 (Liu et al., 2012). The annual decrease in the under five mortality rate from
1990-2010 was 2.1%, compared to the 4.4% necessary to meet the fourth Millennium Development Goal
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(MDG) (Rajaratnam et al., 2010). Therefore, despite recent progress in reducing under five mortality, a
renewed focus on implementing interventions which will allow countries to reach this target is likely to be
required, particularly those interventions which are most cost effective and easy to implement. Measles
vaccination coverage is one of the indicators for monitoring progress towards MDG 4, and further increases
in immunization may provide an opportunity to aid in achieving this goal.
Results in this paper imply that the basic vaccines provide a viable means of achieving progress towards this
target of reducing child mortality. From 1990 to 2010, the number of annual child deaths globally fell from 12
million to 7.6 million (Hill et al., 2012). Over the same time period, the corresponding measles vaccination
global coverage rate rose from 73% to 84%, according to WHO-UNICEF estimates. The corresponding
estimate from our sample indicates that 64% of children were vaccinated against measles in 1986-1990,
compared to 84% in 2006-2010. We were unable to find global estimates for maternal tetanus coverage for the
relevant time period, however our data indicate that 56% of children had mothers who had been vaccinated for
tetanus before pregnancy in 1986-1990, as compared to 60% in 2006-2010. Using the estimates from table 2
implies that the increase in measles and tetanus coverage alone were responsible for a 0.20∗17+0.04∗8 = 3.7%
fall in global mortality. The mean vaccination rate in our data increased from 65% in 1986-1990 to 81%
in 2006-2010, which corresponds to a reduction in mortality of 4.5%. Overall, coverage estimates indicate
that there is substantial scope for further increasing vaccination rates (Pegurri et al., 2005), particularly in
sub-Saharan Africa (Bosch-Capblanch et al., 2012).
It is reasonable to ask whether expanding coverage of measles and maternal tetanus would be cost effective
strategies for reducing child mortality. If measles coverage could be raised a further 16 percentage points to
100%, this would equate to a roughly 3% reduction in mortality, or an estimated reduction of 210,000 deaths
(under the figures provided in Hill et al. (2012)). For maternal tetanus, our estimates imply that increasing
immunization coverage by 40 percentage points to 100% would result in approximately 240,000 fewer deaths.
According to UN estimates, the lowest cost of a single dose MMR vaccine is $2.05, while the lowest
cost for a maternal tetanus dose is $0.05 (see the note to Table 1 for further details). Under the simplifying
assumption that raising measles vaccination coverage by 16% would require an extra 133m∗16% = 21m doses,
and 21m ∗ 2.05 = $43.05m expenditure, this results in an approximate cost per life saved of 43.05m210,000 = $205.
Likewise, for tetanus, assuming that raising coverage by 40% would require an additional 133m∗40% = 53m
doses, and 53m ∗ $0.05 = $2.7m expenditure, results in an approximate cost per life saved of 2.7m240,000 = $11.
While these calculations are based on highly simplified assumptions, and only account for the cost of
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vaccines themselves and not administration or roll-out of expanded programs, these figures nevertheless
provide some indication that increases in vaccination coverage as a means to reduce child mortality and
achieve the targets laid out in the MDGs are likely to be highly cost effective, particularly for maternal
tetanus immunization. For example, the estimated cost of full immunization for BCG, DPT, polio, and
measles in GAVI countries was $4 in 2011 (Gandhi et al., 2013). Moreover, estimates based solely on
direct health benefits may understate the value of vaccines as there are likely to be additional benefits to
society above and beyond their protective effects on mortality (Ba¨rnighausen et al., 2014; Bloom et al.,
2005; Deogaonkar et al., 2012; Ozawa et al., 2012). For example, previous studies have linked increases in
vaccination coverage to improvements in human capital (Bloom et al., 2012; Canning et al., 2011).
There are important limitations associated with estimating the effects of vaccination status from household
surveys (Fine et al., 2009), and future research should adopt methods for further validating the causal
relationship between immunization and mortality (Farrington et al., 2009; Pollard, 2012; Sachdev, 2014), and
further investigating the mechanisms underlying the association between vaccination and all-cause mortality
(Kleinnijenhuis et al., 2012; Ritz et al., 2013). Our results are somewhat smaller than the limited available
evidence on non-specific effects of vaccines from RCTs (Shann, 2013), however this is likely to reflect a
number of drawbacks to the data. First, we estimate cluster level vaccination coverage from the survey,
which could introduce measurement error and attenuation bias. In addition, we rely on maternal reports
of vaccination status when vaccination cards are not available, which could also induce measurement error.
We use a binary indicator for BCG, measles and maternal tetanus, and assign the value one to receiving 3
doses of Polio and 3 doses of DPT. However, there are many potential ways to measure vaccination coverage.
Second, we do not consider the timing or ordering of vaccination, which is also likely to have an impact
on child outcomes (Aaby et al., 2015; Clark and Sanderson, 2009). We did not find any adverse impact of
the DPT vaccine, however we were unable to estimate its relative risk separately from that of Polio. Third,
we do not examine potential interactions or non-linearities in the data. Vaccine efficacy may vary with
country, cluster, family, and child level characteristics (Bishai et al., 2003). The literature has documented
potential effect modification by sex and receipt of vitamin A supplementation (Aaby et al., 2004b; Benn
et al., 2014). Investigating these interactions is an important direction for future research. Finally, our
estimates come from data which are not globally representative, only nationally representative. While we
use all available Demographic and Health Surveys from round 2 on, countries are not sampled randomly, and
therefore any direct comparison between rates estimated in the data and global estimates should be made
with this limitation in mind.
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0 .2 .4 .6 .8 1
Average of All Vaccinations in the Cluster
Source: Demographic and Health Surveys. For BCG, measles, and maternal tetanus, we construct a binary indicator variable
for each child indicating whether they received the relevant vaccine dose. We combine DPT and Polio into a single variable
where each dose counts for 1/6. Therefore, receiving a full schedule of DPT and Polio results in a score of 1. Mean vaccination
coverage is defined as the average of the BCG, DPT/Polio, measles, and maternal tetanus vaccination rates in the cluster.
The data include 68,490 DHS primary sampling unit clusters, based on 149 surveys in 62 countries, and 960,271 children born
between 1985 and 2011.
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0 .2 .4 .6 .8 1
Base Vaccination Rate
Source: Demographic and Health Surveys. The data include 68,490 DHS primary sampling unit clusters, based on 149 surveys in
62 countries, and 960,271 children born between 1985 and 2011. The corrected vaccination rate adjusts for missing immunization
information on children who have died using the procedure described in the main text.
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Table A1: Results for Cluster Vaccination Coverage and Cluster Mortality (Unadjusted for Covariates
other than Country Fixed Effects and Time Trends)
Relative Risk Relative Risk Relative Risk Relative Risk
Cluster Level Cluster Level Cluster Level Cluster Level
Under 5 Mortality Under 5 Mortality Under 5 Mortality Under 5 Mortality
Variables (95% CI) (95% CI) (95% CI) (95% CI)
Cluster Vaccination Average Coverage 0.38 (0.36 - 0.40) 0.37 (0.35 - 0.38)
Cluster BCG Coverage 1.06 (0.98 - 1.14) 1.06 (0.98 - 1.15)
Cluster DPT Polio Coverage 0.85 (0.77 - 0.93) 0.86 (0.79 - 0.94)
Cluster Measles Coverage 0.71 (0.66 - 0.77) 0.70 (0.65 - 0.75)
Cluster Maternal Tetanus Coverage 0.57 (0.53 - 0.58) 0.56 (0.53 - 0.58)
Corrected for Missing Data on Children who Died No Yes No Yes
Country Fixed Effects and Country Time Trends Yes Yes Yes Yes
Full Set of Control Variables No No No No
Observations 68,490 68,490 68,490 68,490
Note: Demographic and Health Survey data are available from www.dhsprogram.com. All variables are averages at the level of
the DHS primary sampling unit cluster, based on 149 surveys in 62 countries, and 960,271 children born between 1985 and 2011.
Coefficients illustrate the relative risk of moving from 0% vaccination coverage to 100% coverage (on the mortality of children
born in the 5 years prior to interview). Columns 1 and 3 are based on the raw vaccination coverage in a cluster (defined as the
proportion of children one year or older who have received the relevant doses), while columns 2 and 4 adjust the vaccination
data for the selection effect due to non-reporting of vaccination status of children who have died. Models control for country
fixed effects and country time trends.
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Table A2: Full Results for Cluster Vaccination Coverage and Cluster Mortality
Relative Risk Relative Risk Relative Risk Relative Risk
Cluster Level Cluster Level Cluster Level Cluster Level
Under 5 Mortality Under 5 Mortality Under 5 Mortality Under 5 Mortality
Variables (95% CI) (95% CI) (95% CI) (95% CI)
Cluster Vaccination Average Coverage 0.76 (0.71 - 0.81) 0.73 (0.68 - 0.77)
Cluster BCG Coverage 1.04 (0.96 - 1.12) 1.03 (0.96 - 1.11)
Cluster DPT Polio Coverage 0.97 (0.89 - 1.06) 0.97 (0.89 - 1.06)
Cluster Measles Coverage 0.83 (0.77 - 0.89) 0.83 (0.78 - 0.89)
Cluster Maternal Tetanus Coverage 0.92 (0.86 - 0.97) 0.92 (0.86 - 0.97)
Wealth Index: Omitted=Highest
Cluster Mean Lowest Quintile 1.12 (1.05 - 1.19) 1.11 (1.04 - 1.19) 1.12 (1.05 - 1.19) 1.12 (1.05 - 1.19)
Cluster Mean Second Quintile 1.12 (1.06 - 1.20) 1.12 (1.05 - 1.19) 1.12 (1.06 - 1.20) 1.12 (1.06 - 1.20)
Cluster Mean Third Quintile 1.06 (1.00 - 1.13) 1.06 (1.00 - 1.12) 1.06 (1.00 - 1.13) 1.06 (1.00 - 1.13)
Cluster Mean Fourth Quintile 1.08 (1.02 - 1.15) 1.08 (1.02 - 1.14) 1.08 (1.02 - 1.14) 1.08 (1.02 - 1.14)
Cluster Mean Year of Birth 0.14 (0.13 - 0.16) 0.14 (0.13 - 0.16) 0.14 (0.13 - 0.16) 0.14 (0.13 - 0.16)
Cluster Mean Sex of Child – Female 0.93 (0.90 - 0.95) 0.93 (0.90 - 0.95) 0.92 (0.90 - 0.95) 0.92 (0.90 - 0.95)
Cluster Mean Was not Multiple Birth 0.90 (0.85 - 0.96) 0.90 (0.85 - 0.96) 0.90 (0.85 - 0.96) 0.90 (0.85 - 0.96)
Place of Birth: Omitted= Own Home
Cluster Mean Other Home 1.01 (0.93 - 1.11) 1.01 (0.93 - 1.11) 1.01 (0.92 - 1.11) 1.01 (0.92 - 1.11)
Cluster Mean Government Hospital 0.82 (0.78 - 0.87) 0.83 (0.78 - 0.87) 0.83 (0.78 - 0.88) 0.83 (0.78 - 0.88)
Cluster Mean Government Health Center 0.87 (0.82 - 0.91) 0.87 (0.83 - 0.92) 0.87 (0.82 - 0.92) 0.87 (0.82 - 0.92)
Cluster Mean Private Hospital or Clinic 0.80 (0.75 - 0.86) 0.80 (0.75 - 0.86) 0.80 (0.74 - 0.86) 0.80 (0.74 - 0.86)
Cluster Mean Other and Unknown 1.97 (1.68 - 2.31) 1.96 (1.67 - 2.30) 1.99 (1.69 - 2.33) 1.98 (1.69 - 2.32)
Birth Interval: Omitted=12-17 Months
Cluster Mean Birth Interval First Birth 0.14 (0.12 - 0.17) 0.14 (0.12 - 0.17) 0.14 (0.12 - 0.17) 0.14 (0.12 - 0.17)
Cluster Mean Birth Interval 1-11 5.15 (3.79 - 7.00) 5.09 (3.75 - 6.92) 5.15 (3.79 - 7.00) 5.15 (3.79 - 7.00)
Cluster Mean Birth Interval 18-23 0.22 (0.19 - 0.26) 0.22 (0.19 - 0.26) 0.22 (0.19 - 0.26) 0.22 (0.19 - 0.26)
Cluster Mean Birth Interval 24+ 0.12 (0.11 - 0.14) 0.12 (0.11 - 0.14) 0.12 (0.11 - 0.14) 0.12 (0.11 - 0.14)
Cluster Mean Number of Siblings 1.07 (1.06 - 1.09) 1.07 (1.05 - 1.09) 1.07 (1.05 - 1.09) 1.07 (1.05 - 1.09)
Mother’s Age: Omitted=15-19
Cluster Mean Mother’s Age 20-24 0.77 (0.68 - 0.86) 0.77 (0.68 - 0.86) 0.77 (0.69 - 0.87) 0.77 (0.69 - 0.87)
Cluster Mean Mother’s Age 25-29 0.63 (0.56 - 0.71) 0.63 (0.56 - 0.72) 0.64 (0.56 - 0.72) 0.63 (0.56 - 0.72)
Cluster Mean Mother’s Age 30-34 0.59 (0.52 - 0.67) 0.59 (0.52 - 0.67) 0.59 (0.52 - 0.68) 0.59 (0.52 - 0.68)
Cluster Mean Mother’s Age 35-39 0.59 (0.51 - 0.68) 0.59 (0.51 - 0.68) 0.59 (0.51 - 0.68) 0.59 (0.51 - 0.68)
Cluster Mean Mother’s Age 40-44 0.61 (0.52 - 0.72) 0.61 (0.52 - 0.73) 0.62 (0.52 - 0.73) 0.62 (0.52 - 0.73)
Cluster Mean Mother’s Age 45-49 0.70 (0.55 - 0.89) 0.70 (0.55 - 0.89) 0.70 (0.55 - 0.89) 0.70 (0.55 - 0.89)
Cluster Mean Rural Place of Residence 0.95 (0.93 - 0.98) 0.95 (0.93 - 0.98) 0.95 (0.93 - 0.98) 0.95 (0.93 - 0.98)
Mother’s Highest Education: Omitted=None
Cluster Mean Primary 0.97 (0.92 - 1.03) 0.97 (0.92 - 1.03) 0.97 (0.92 - 1.03) 0.97 (0.92 - 1.03)
Cluster Mean Secondary 0.84 (0.78 - 0.90) 0.84 (0.78 - 0.90) 0.84 (0.78 - 0.90) 0.84 (0.78 - 0.90)
Cluster Mean Higher Education 0.71 (0.60 - 0.82) 0.71 (0.61 - 0.82) 0.71 (0.60 - 0.82) 0.71 (0.60 - 0.82)
Cluster Mean Missing 0.49 (0.11 - 2.06) 0.48 (0.11 - 2.05) 0.48 (0.11 - 2.05) 0.49 (0.11 - 2.06)
Cluster Mean Flush Toilet Access 0.90 (0.86 - 0.95) 0.90 (0.86 - 0.95) 0.90 (0.86 - 0.95) 0.90 (0.86 - 0.95)
Cluster Mean Piped Water in House 0.98 (0.95 - 1.01) 0.98 (0.95 - 1.01) 0.98 (0.95 - 1.01) 0.98 (0.95 - 1.01)
Partner Education: Omitted=None
Cluster Mean Primary 1.10 (1.03 - 1.17) 1.10 (1.03 - 1.17) 1.09 (1.03 - 1.16) 1.09 (1.03 - 1.16)
Cluster Mean Secondary 0.99 (0.92 - 1.06) 0.99 (0.92 - 1.06) 0.98 (0.92 - 1.05) 0.98 (0.92 - 1.05)
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Relative Risk Relative Risk Relative Risk Relative Risk
Cluster Level Cluster Level Cluster Level Cluster Level
Under 5 Mortality Under 5 Mortality Under 5 Mortality Under 5 Mortality
Variables (95% CI) (95% CI) (95% CI) (95% CI)
Cluster Mean Higher Education 0.91 (0.80 - 1.02) 0.91 (0.80 - 1.02) 0.91 (0.80 - 1.02) 0.91 (0.80 - 1.02)
Cluster Mean Missing 1.12 (1.00 - 1.25) 1.12 (1.00 - 1.25) 1.12 (1.00 - 1.25) 1.11 (1.00 - 1.24)
Marital Status: Omitted=Married
Cluster Mean Never Married 1.11 (0.93 - 1.31) 1.11 (0.93 - 1.31) 1.11 (0.94 - 1.31) 1.11 (0.94 - 1.32)
Cluster Mean Living Together 1.11 (1.04 - 1.17) 1.11 (1.04 - 1.17) 1.10 (1.04 - 1.17) 1.10 (1.04 - 1.17)
Cluster Mean Widowed 1.80 (1.44 - 2.24) 1.79 (1.44 - 2.23) 1.79 (1.43 - 2.23) 1.79 (1.43 - 2.23)
Cluster Mean Divorced 1.90 (1.57 - 2.31) 1.90 (1.57 - 2.31) 1.90 (1.56 - 2.30) 1.90 (1.56 - 2.30)
Cluster Mean Not Living Together 1.67 (1.47 - 1.90) 1.67 (1.47 - 1.90) 1.67 (1.47 - 1.90) 1.67 (1.47 - 1.90)
Religion: Omitted=Christian
Cluster Mean Religion Muslim 1.01 (0.97 - 1.05) 1.01 (0.97 - 1.05) 1.01 (0.97 - 1.05) 1.01 (0.97 - 1.05)
Cluster Mean Religion Jewish 0.85 (0.64 - 1.15) 0.86 (0.64 - 1.15) 0.85 (0.64 - 1.15) 0.85 (0.64 - 1.15)
Cluster Mean Religion Buddhist 0.86 (0.73 - 1.01) 0.86 (0.73 - 1.01) 0.86 (0.73 - 1.00) 0.86 (0.73 - 1.00)
Cluster Mean Religion Hindu 1.40 (1.30 - 1.51) 1.40 (1.30 - 1.51) 1.40 (1.30 - 1.51) 1.40 (1.30 - 1.51)
Cluster Mean Religion Sikh 1.13 (0.86 - 1.50) 1.14 (0.86 - 1.51) 1.15 (0.87 - 1.52) 1.15 (0.87 - 1.52)
Cluster Mean Religion Traditional 1.05 (0.95 - 1.16) 1.04 (0.95 - 1.15) 1.04 (0.95 - 1.15) 1.04 (0.95 - 1.15)
Cluster Mean Religion Other 1.07 (0.98 - 1.18) 1.07 (0.98 - 1.17) 1.08 (0.98 - 1.18) 1.08 (0.98 - 1.18)
Cluster Mean Religion None 0.87 (0.78 - 0.97) 0.87 (0.78 - 0.96) 0.86 (0.78 - 0.96) 0.87 (0.78 - 0.96)
Cluster Mean Unknown/Missing 1.07 (1.02 - 1.14) 1.08 (1.02 - 1.14) 1.07 (1.01 - 1.13) 1.07 (1.01 - 1.13)
Cluster Mean Months Since Birth 0.99 (0.99 - 0.99) 0.99 (0.99 - 0.99) 0.99 (0.99 - 0.99) 0.99 (0.99 - 0.99)
Had Ante-Natal Visit: Omitted=No Visit
Cluster Mean Had Ante-Natal Visit 0.86 (0.81 - 0.91) 0.87 (0.82 - 0.93) 0.85 (0.80 - 0.91) 0.85 (0.80 - 0.91)
Cluster Mean Ante-Natal Visit Missing 1.32 (1.21 - 1.45) 1.32 (1.21 - 1.45) 1.29 (1.18 - 1.42) 1.29 (1.18 - 1.42)
Corrected for Missing Data on Children who Died No Yes No Yes
Country Fixed Effects and Country Time Trends Yes Yes Yes Yes
Number of clusters 68,490 68,490 68,490 68,490
Note: Demographic and Health Survey data are available from www.dhsprogram.com. All variables are averages at the level of
the DHS primary sampling unit cluster, based on 149 surveys in 62 countries, and 960,271 children born between 1985 and 2011.
Coefficients illustrate the relative risk of moving from 0% vaccination coverage to 100% coverage (on the mortality of children
born in the 5 years prior to interview). Columns 1 and 3 are based on the raw vaccination coverage in a cluster (defined as the
proportion of children one year or older who have received the relevant doses), while columns 2 and 4 adjust the vaccination
data for the selection effect due to non-reporting of vaccination status of children who have died.
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Table A3: Corrected Cluster Vaccination Coverage Rates
Cluster Vaccination Coverage Median Mean SD N
Measles
Base 88.89% 79.77% 25.65% 68,490
Iteration 1 88.83% 79.64% 25.75% 68,490
Iteration 2 88.83% 79.64% 25.75% 68,490
Iteration 3 88.83% 79.64% 25.75% 68,490
Iteration 4 88.83% 79.64% 25.75% 68,490
Iteration 5 88.83% 79.64% 25.75% 68,490
Iteration 6 88.83% 79.64% 25.75% 68,490
Iteration 7 88.83% 79.64% 25.75% 68,490
Iteration 8 88.83% 79.64% 25.75% 68,490
Iteration 9 88.83% 79.64% 25.75% 68,490
Iteration 10 88.83% 79.64% 25.75% 68,490
DPT Polio
Base 88.89% 81.92% 21.22% 68,490
Iteration 1 88.89% 81.91% 21.23% 68,490
Iteration 2 88.89% 81.91% 21.23% 68,490
Iteration 3 88.89% 81.91% 21.23% 68,490
Iteration 4 88.89% 81.91% 21.23% 68,490
Iteration 5 88.89% 81.91% 21.23% 68,490
Iteration 6 88.89% 81.91% 21.23% 68,490
Iteration 7 88.89% 81.91% 21.23% 68,490
Iteration 8 88.89% 81.91% 21.23% 68,490
Iteration 9 88.89% 81.91% 21.23% 68,490
Iteration 10 88.89% 81.91% 21.23% 68,490
Table A3 – Continued on the Next Page
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Cluster Vaccination Coverage Median Mean SD N
BCG
Base 100.00% 87.28% 22.22% 68,490
Iteration 1 100.00% 87.30% 22.20% 68,490
Iteration 2 100.00% 87.29% 22.21% 68,490
Iteration 3 100.00% 87.29% 22.21% 68,490
Iteration 4 100.00% 87.29% 22.21% 68,490
Iteration 5 100.00% 87.29% 22.21% 68,490
Iteration 6 100.00% 87.29% 22.21% 68,490
Iteration 7 100.00% 87.29% 22.21% 68,490
Iteration 8 100.00% 87.29% 22.21% 68,490
Iteration 9 100.00% 87.29% 22.21% 68,490
Iteration 10 100.00% 87.29% 22.21% 68,490
Mean Vaccination
Base 81.30% 76.80% 19.34% 68,490
Iteration 1 81.25% 76.64% 19.45% 68,490
Iteration 2 81.25% 76.62% 19.46% 68,490
Iteration 3 81.25% 76.61% 19.46% 68,490
Iteration 4 81.25% 76.61% 19.46% 68,490
Iteration 5 81.25% 76.61% 19.46% 68,490
Iteration 6 81.25% 76.61% 19.46% 68,490
Iteration 7 81.25% 76.61% 19.46% 68,490
Iteration 8 81.25% 76.61% 19.46% 68,490
Iteration 9 81.25% 76.61% 19.46% 68,490
Iteration 10 81.25% 76.61% 19.46% 68,490
The base vaccination coverage rate is the raw cluster vaccination rate in the data which excludes children who have died. The
vaccination coverage rate in iterations 1-10 corrects for this missing data using the procedure described in the main text.
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Table A4: DHS Surveys Included in the Analysis
DHS Survey: Year DHS Survey: Year
Albania Year: 2008-2009 Central African Republic Year: 1994-1995
Bangladesh Year: 1993-1994 Chad Year: 1996-1997
Bangladesh Year: 1996-1997 Chad Year: 2004
Bangladesh Year: 1999-2000 Colombia Year: 1990
Bangladesh Year: 2004 Colombia Year: 1995
Bangladesh Year: 2007 Colombia Year: 2000
Benin Year: 1996 Colombia Year: 2005
Benin Year: 2001 Colombia Year: 2010
Benin Year: 2006 Comoros Year: 1996
Bolivia Year: 1994 Congo Democratic Republic Year: 2007
Bolivia Year: 1998 Congo (Brazzaville) Year: 2005
Bolivia Year: 2003 Cote d’Ivoire Year: 1994
Bolivia Year: 2008 Cote d’Ivoire Year: 1998-1999
Brazil Year: 1996 Dominican Republic Year: 1996
Burkina Faso Year: 1993 Dominican Republic Year: 1999
Burkina Faso Year: 1998-1999 Dominican Republic Year: 2002
Burkina Faso Year: 2003 Dominican Republic Year: 2007
Burkina Faso Year: 2010 Egypt Year: 1995
Burundi Year: 2010 Egypt Year: 2000
Cambodia Year: 2000 Egypt Year: 2005
Cambodia Year: 2005 Egypt Year: 2008
Cambodia Year: 2010 Ethiopia Year: 2000
Cameroon Year: 1991 Ethiopia Year: 2005
Cameroon Year: 1998 Ethiopia Year: 2011
Cameroon Year: 2004 Gabon Year: 2000
Cameroon Year: 2011 Ghana Year: 1993
Ghana Year: 1998 Lesotho Year: 2009
Ghana Year: 2003 Liberia Year: 2007
Ghana Year: 2008 Madagascar Year: 1997
Guatemala Year: 1995 Madagascar Year: 2003-2004
Guinea Year: 1999 Madagascar Year: 2008-2009
Guinea Year: 2005 Malawi Year: 1992
Guyana Year: 2009 Malawi Year: 2000
Haiti Year: 1994 Malawi Year: 2004
Haiti Year: 2000 Malawi Year: 2010
Haiti Year: 2005-2006 Maldives Year: 2009
Honduras Year: 2005-2006 Mali Year: 2001
India Year: 1992-1993 Mali Year: 2006
India Year: 1998-1999 Moldova Year: 2005
India Year: 2005-2006 Morocco Year: 1992
Indonesia Year: 1997 Morocco Year: 2003-2004
Indonesia Year: 2002-2003 Mozambique Year: 1997
Indonesia Year: 2007 Mozambique Year: 2003
Jordan Year: 1990 Namibia Year: 1992
Jordan Year: 1997 Namibia Year: 2006-2007
Jordan Year: 2002 Nepal Year: 1996
Table A4 – Continued on the Next Page
29
DHS Survey: Year DHS Survey: Year
Jordan Year: 2007 Nepal Year: 2001
Kenya Year: 1993 Nepal Year: 2006
Kenya Year: 1998 Nepal Year: 2011
Kenya Year: 2003 Nicaragua Year: 1998
Kenya Year: 2008-2009 Nicaragua Year: 2001
Lesotho Year: 2004 Niger Year: 1998
Niger Year: 2006 Tanzania Year: 2004-2005
Nigeria Year: 1990 Tanzania Year: 2010
Nigeria Year: 2003 Timor Leste Year: 2009-2010
Nigeria Year: 2008 Togo Year: 1998
Pakistan Year: 1990 Turkey Year: 1993
Pakistan Year: 2006-2007 Turkey Year: 1998
Paraguay Year: 1990 Uganda Year: 1995
Peru Year: 1991-1992 Uganda Year: 2000-2001
Peru Year: 1996 Uganda Year: 2006
Peru Year: 2000 Uganda Year: 2011
Philippines Year: 1993 Vietnam Year: 1997
Philippines Year: 1998 Vietnam Year: 2002
Philippines Year: 2003 Zambia Year: 1996
Philippines Year: 2008 Zambia Year: 2001-2002
Rwanda Year: 1992 Zambia Year: 2007
Rwanda Year: 2000 Zimbabwe Year: 1994
Rwanda Year: 2005 Zimbabwe Year: 1999
Rwanda Year: 2010 Zimbabwe Year: 2005-2006
Sao Tome and Principe Year: 2008-2009 Zimbabwe Year: 2010-2011
Senegal Year: 2005
Senegal Year: 2010-2011
Sierra Leone Year: 2008




Note: Demographic and Health Survey data are available from www.dhsprogram.com.
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